Zogenix, Inc. (OQ:ZGNX)

Jun 25, 2020 11:05 pm ET
FDA Approves FINTEPLA® (fenfluramine) for the Treatment of Seizures Associated with Dravet Syndrome
EMERYVILLE, Calif., June 25, 2020 /PRNewswire/ -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved FINTEPLA® (fenfluramine) oral solution, CIV for the treatment of seizures associated with Dravet syndrome in patients 2 years of age and older. FINTEPLA will be launched through a restricted distribution program, called the FINTEPLA Risk Evaluation and Mitigation Strategy (REMS) Program, and is expected to be available through Zogenix's specialty pharmacy partner by the ...
Jun 25, 2020 08:49 pm ET
FDA Approves FINTEPLA® (fenfluramine) for the Treatment of Seizures Associated with Dravet Syndrome
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved FINTEPLA® (fenfluramine) oral solution, CIV for the treatment of seizures...
Jun 12, 2020 08:00 am ET
Zogenix Introduces New Resources for Dravet Syndrome Siblings
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced the introduction in the U.S. of a new suite of materials to better support and celebrate siblings of those living with Dravet syndrome....
May 06, 2020 08:00 am ET
Zogenix to Participate in the BofA Securities 2020 Virtual Healthcare Conference
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., will participate in a fireside chat on Wednesday, May 13, 2020, at the BofA Securities 2020 Virtual...
May 05, 2020 04:01 pm ET
Zogenix Provides Corporate Update and Reports First Quarter 2020 Financial Results
Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced financial results for the three months ended March 31, 2020, and provided a corporate update. The Company will host a conference call...
Apr 28, 2020 08:00 am ET
Zogenix to Release First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 5
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the first quarter ended March 31, 2020, after the market close, and will host a corporate...
Apr 20, 2020 08:00 am ET
Zogenix Appoints Shawnte Mitchell as Executive Vice President, General Counsel & Secretary
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced it has appointed Shawnte M. Mitchell to the role of Executive Vice President, General Counsel and Secretary. In this role, Ms. Mitchell...
Apr 15, 2020 08:00 am ET
Zogenix to Host Investor Conference Call and Webcast on Two Studies Evaluating FINTEPLA® in Dravet Syndrome and Sunflower Syndrome
Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it will host an investor conference call and webcast on two studies evaluating its investigational drug, FINTEPLA®, in Dravet...
Mar 06, 2020 04:05 pm ET
Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it has closed its previously announced underwritten public offering of 9,798,000 shares of its common stock, including 1,278,000...
Mar 03, 2020 09:05 pm ET
Zogenix Prices Public Offering of Common Stock
Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it has priced an underwritten public offering of 8,520,000 shares of its common stock at a price to the public of $23.50 per...
Mar 03, 2020 05:07 pm ET
Zogenix Announces Proposed Public Offering of Common Stock
Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public...
Mar 02, 2020 04:01 pm ET
Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2019 Financial Results
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today provided a corporate update and announced financial results for the quarter and full-year ended December 31, 2019. The Company will host a...
Feb 27, 2020 08:00 am ET
Zogenix Announces FDA Extension of Review Period for FINTEPLA® in Dravet Syndrome
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for FINTEPLA® for...
Feb 24, 2020 08:00 am ET
Zogenix to Release Fourth Quarter and Full-Year 2019 Financial Results and Host Conference Call and Webcast on March 2
Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2019, after the market close, and...
Feb 06, 2020 04:01 pm ET
Zogenix Announces Positive Top-line Results from Global Pivotal Phase 3 Trial of FINTEPLA® for the Treatment of Lennox-Gastaut Syndrome
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today reported positive top-line results from its global Phase 3 clinical trial (Study 1601) of its lead investigational therapy, FINTEPLA® (ZX008,...
Dec 17, 2019 07:04 pm ET
The Lancet Publishes Phase 3 Trial Results for Zogenix Investigational Drug FINTEPLA® in Dravet Syndrome
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that The Lancet has published the results of its Phase 3 clinical trial, Study 1, of the Company’s investigational drug, FINTEPLA®...
Dec 05, 2019 08:15 am ET
Zogenix to Host Investor Update Lunch on FINTEPLA® at the American Epilepsy Society 2019 Annual Meeting
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will host an Investor Update Lunch on its investigational drug, FINTEPLA® (ZX008, fenfluramine oral solution), on Monday,...
Dec 02, 2019 04:01 pm ET
JAMA Neurology Publishes Phase 3 Study of Zogenix Investigational Drug FINTEPLA® in Dravet Syndrome Patients Taking Stiripentol-Containing Antiepileptic Drug Regimens
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that JAMA Neurology has published the results of Zogenix’s Phase 3 study (Study 1504) of the investigational drug, FINTEPLA® (ZX008,...
Dec 02, 2019 08:00 am ET
Zogenix to Present New Data for Its Investigational Drug FINTEPLA® at the American Epilepsy Society Annual Meeting
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, announced that data from eight abstracts related to its investigational therapy, FINTEPLA® (ZX008, fenfluramine oral solution), for the treatment of...
Nov 27, 2019 08:00 am ET
Zogenix to Participate in the 31st Annual Piper Jaffray Healthcare Conference
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., will participate in a fireside chat on Thursday, December 5, 2019, at the 31st Annual Piper Jaffray...
Nov 25, 2019 08:00 am ET
Zogenix Announces FDA Acceptance for Filing of New Drug Application and Priority Review for FINTEPLA® for the Treatment of Dravet Syndrome
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s New Drug Application (NDA) for FINTEPLA® (ZX008,...
Nov 21, 2019 02:42 pm ET
Shareholder Alert: Robbins LLP Reminds Investors Zogenix, Inc. (ZGNX) Sued for Misleading Shareholders
Shareholder rights law firm Robbins LLP reminds investors that a purchaser of Zogenix, Inc. (NASDAQ: ZGNX) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between February 6, 2019 and April 8, 2019. Zogenix is a pharmaceutical company that develops and commercializes therapies for the treatment of transfor
Nov 12, 2019 08:00 am ET
Zogenix to Present at Two Investor Conferences in November
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and CEO, and Michael P. Smith, Executive Vice President, CFO, Treasurer and Secretary, will...
Nov 07, 2019 04:01 pm ET
Zogenix Provides Corporate Update and Reports Third Quarter 2019 Financial Results
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced financial results for the three and nine months ended September 30, 2019, and provided a corporate update. The Company will host a...
Oct 31, 2019 08:00 am ET
Zogenix to Release Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 7
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three and nine months ended September 30, 2019, after the market close, and will host...
Oct 25, 2019 09:00 am ET
Zogenix Announces New Positive Data for Its Investigational Drug FINTEPLA® in Dravet Syndrome
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced positive new data for its investigational drug, FINTEPLA® (ZX008, fenfluramine), for the treatment of seizures associated with Dravet...
Oct 21, 2019 08:00 am ET
Zogenix Announces Presentation of New Data for FINTEPLA® for the Treatment of Dravet Syndrome at the Child Neurology Society Annual Meeting
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, announced that five posters related to its investigational therapy, FINTEPLA® (ZX008, fenfluramine oral solution), will be presented at the 48th Annual...
Oct 08, 2019 08:28 pm ET
Bragar Eagel & Squire is Investigating Certain Officers and Directors of CBL & Associates Properties, EQT Corporation, and Zogenix and Encourages Investors to Contact the Firm
Bragar Eagel & Squire is investigating certain officers and directors of CBL & Associates Properties, Inc. (NYSE: CBL), EQT Corporation (NYSE: EQT), and Zogenix, Inc. (NASDAQ: ZGNX) on behalf of long-term stockholders.  More information about each...
Oct 07, 2019 08:00 am ET
Zogenix Presents Positive Clinical Study Results for Investigational Treatment for TK2 Deficiency
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, and its wholly-owned subsidiary, Modis Therapeutics,  presented positive top-line results from its pivotal Phase 2 RETRO study at the recent World...
Sep 26, 2019 07:00 am ET
Zogenix Resubmits New Drug Application for FINTEPLA® for the Treatment of Dravet Syndrome to U.S. Food and Drug Administration
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has resubmitted its New Drug Application (NDA) for FINTEPLA® (ZX008, fenfluramine) for the treatment of seizures associated...
Sep 23, 2019 05:23 pm ET
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zogenix, Inc. (“Zogenix” or “the Company”) (NASDAQ: ZGNX) for violations of the securities laws. The...
Sep 18, 2019 08:49 pm ET
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Orion Group Holdings, Zogenix, and Apyx and Encourages Investors to Contact the Firm
Bragar Eagel & Squire is investigating certain officers and directors of Orion Group Holdings, Inc. (NYSE: ORN), Zogenix, Inc. (NASDAQ: ZGNX), and Apyx Medical Corporation (NASDAQ: APYX) on behalf of long-term stockholders. More information about...
Sep 16, 2019 05:10 pm ET
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zogenix, Inc. (“Zogenix” or “the Company”) (NASDAQ: ZGNX) for violations of §§10(b) and 20(a) of the Securities...
Sep 09, 2019 08:00 am ET
Zogenix Completes Acquisition of Modis Therapeutics, Inc.
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has successfully completed its acquisition of Modis Therapeutics, Inc., a privately-held biopharmaceutical company, and added...
Sep 04, 2019 09:04 pm ET
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zogenix, Inc. (“Zogenix” or “the Company”) (NASDAQ: ZGNX) for violations of §§10(b) and 20(a) of the Securities...
Sep 03, 2019 02:49 pm ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zogenix, Inc. (“Zogenix” or “the Company”) (NASDAQ:
Aug 29, 2019 10:19 am ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zogenix, Inc. (“Zogenix” or “the Company”) (NASDAQ:
Aug 26, 2019 07:00 am ET
Zogenix Announces Acquisition of Modis Therapeutics, Inc.
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has entered into a definitive agreement to acquire Modis Therapeutics, Inc., a privately held biopharmaceutical company...
Aug 06, 2019 04:01 pm ET
Zogenix Provides Corporate Update and Reports Second Quarter 2019 Financial Results
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced financial results for the three and six months ended June 30, 2019, and provided a corporate update. The Company will host a conference...
Jul 30, 2019 08:00 am ET
Zogenix to Release Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 6
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three and six months ended June 30, 2019, after the market close, and will host a...
Jul 08, 2019 08:00 am ET
Zogenix Completes Enrollment in Phase 3 Trial of FINTEPLA® in Lennox-Gastaut Syndrome
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has completed enrollment for, and randomized the last patient into the treatment period of, Study 1601, the Company’s Phase 3...
Jun 27, 2019 08:00 am ET
Zogenix Announces FDA Agreement to Proceed with Resubmission of FINTEPLA® NDA
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that following receipt of final minutes from the U.S. Food and Drug Administration (FDA) from the Type A meeting held on May 30, 2019,...
Jun 11, 2019 02:42 pm ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Zogenix, Inc.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 11, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Zogenix, Inc. (“Zogenix” or the “Company”) (NASDAQ: ZGNX) investors who purchased...
Jun 07, 2019 03:00 pm ET
Zogenix, Inc. (ZGNX), BrightView Holdings, Inc. (BV) & Taronis Technologies, Inc. f/k/a MagneGas Applied Technology (TRNX) - Bronstein, Gewirtz & Grossman, LLC Notifies of Class Actions
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Jun 07, 2019 11:06 am ET
ZGNX ALERT:  Zhang Investor Law Reminds Investors of June 11 Deadline in Securities Class Action Lawsuit Against Zogenix, Inc. – ZGNX
Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Zogenix, Inc. (NASDAQ: ZGNX) from February 6, 2019 through April 8, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover...
Jun 06, 2019 08:11 pm ET
ZGNX and APYX DEADLINE ALERT: Hagens Berman Reminds APYX and ZGNX Investors of Lead Plaintiff Deadlines
Hagens Berman Sobol Shapiro LLP reminds investors in ZGNX and APYX of immediately approaching lead plaintiff deadlines in pending securities class actions. Zogenix, Inc. (NASDAQ: ZGNX)CLASS PERIOD: Feb. 6, 2019 - April 8, 2019LEAD PLAINTIFF...
Jun 06, 2019 09:50 am ET
CLASS ACTION UPDATE for ZGNX, MWA, KSHB and SCOR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Jun 05, 2019 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Orion, Zogenix, BrightView, and Eventbrite and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Orion Group Holdings, Inc., Zogenix, Inc., BrightView Holdings, Inc., and Eventbrite, Inc.  Stockholders have until the...
Jun 05, 2019 07:01 pm ET
ZGNX NOTICE: ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Announces Investigation of Securities Claims Against Zogenix, Inc. Investors with Losses in Excess of $100K are Encouraged to Contact the Firm – ZGN
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Zogenix, Inc. (NASDAQ: ZGNX) resulting from allegations that Zogenix may have issued materially misleading business information to the investing public.
Jun 05, 2019 06:39 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zogenix, Inc. of Class Action Lawsuit and Upcoming Deadline – ZGNX
Pomerantz LLP announces that a class action lawsuit has been filed against Zogenix, Inc. (“Zogenix” or the “Company”) (NASDAQ: ZGNX) and certain of its officers and directors. The class action, filed in United States District Court, United District...
Jun 04, 2019 03:47 pm ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Zogenix, Inc.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 11, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Zogenix, Inc.  (“Zogenix” or the “Company”) (NASDAQ: ZGNX) investors who purchased...
Jun 04, 2019 09:56 am ET
7-DAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zogenix, Inc. (“Zogenix” or “the Company”) (NASDAQ: ZGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act...
Jun 04, 2019 09:19 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ZGNX, INVVY, JMIA and XENT
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jun 03, 2019 03:01 pm ET
Pawar Law Group Reminds Investors of Deadline in Securities Class Action Lawsuit Against Zogenix, Inc. – ZGNX
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Zogenix, Inc. (NASDAQ: ZGNX) from February 6, 2019 through April 8, 2019, inclusive (the “Class Period”). The lawsuit seeks to...
May 31, 2019 08:09 pm ET
CLASS ACTION UPDATES for BA, CRCM, ZGNX, INVVY: Hagens Berman Reminds Investors of Class Actions on Behalf of Shareholders
Hagens Berman Sobol Shapiro LLP reminds BA, CRCM, ZGNX, INVVY investors that class action lawsuits have commenced on behalf of investors in the following companies and lead plaintiff filing deadlines are approaching. The Boeing Company (NYSE:...
May 31, 2019 03:00 pm ET
Zogenix, Inc. (ZGNX), BrightView Holdings, Inc. (BV) &  Taronis Technologies, Inc. f/k/a MagneGas Applied Technology (TRNX) - Bronstein, Gewirtz & Grossman, LLC Announces Class Actions
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
May 31, 2019 02:27 pm ET
ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Zogenix, Inc. Investors of Important June 11th Deadline in Securities Class Action – ZGNX
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zogenix, Inc. (NASDAQ: ZGNX) from February 6, 2019 through April 8, 2019, inclusive (the “Class Period”) of the important June 11, 2019 lead plaintiff...
May 31, 2019 09:55 am ET
CLASS ACTION UPDATE for EB, FSNN, ZGNX and XENT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
May 30, 2019 09:15 am ET
CLASS ACTION UPDATE for WSR, ZGNX, LYFT and XENT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
May 29, 2019 10:10 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Orion, Zogenix, BrightView, and Eventbrite and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Orion Group Holdings, Inc., Zogenix, Inc., BrightView Holdings, Inc., and Eventbrite, Inc.  Stockholders have until the...
May 27, 2019 10:30 am ET
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zogenix, Inc. (“Zogenix” or “the Company”) (NASDAQ: ZGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act...
May 26, 2019 09:00 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zogenix, Inc. of Class Action Lawsuit and Upcoming Deadline– ZGNX
Pomerantz LLP announces that a class action lawsuit has been filed against Zogenix, Inc. (“Zogenix” or the “Company”) (NASDAQ: ZGNX) and certain of its officers and directors.  The class action, filed in United States District Court, United...
May 23, 2019 08:09 pm ET
ZGNX CLASS ACTION REMINDER: Hagens Berman Reminds Zogenix (ZGNX) Investors of Class Action of Upcoming Deadline
Hagens Berman Sobol Shapiro LLP, with nine offices in eight cities around the country and eighty attorneys, reminds investors in Zogenix, Inc. (NASDAQ: ZGNX) of the upcoming June 11, 2019 lead plaintiff movant deadline in the securities class...
May 23, 2019 11:36 am ET
ZGNX JUNE 11th DEADLINE: Rosen Law Firm Reminds Zogenix, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses over $100K to Contact the Firm – ZGNX
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zogenix, Inc. (NASDAQ: ZGNX) from February 6, 2019 through April 8, 2019, inclusive (the “Class Period”) of the important June 11, 2019 lead plaintiff...
May 22, 2019 11:12 am ET
ZGNX DEADLINE: Pawar Law Group Reminds Investors of Deadline in Securities Class Action Lawsuit Against Zogenix, Inc. – ZGNX
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Zogenix, Inc. (NASDAQ: ZGNX) from February 6, 2019 through April 8, 2019, inclusive (the “Class Period”). The lawsuit seeks to...
May 22, 2019 10:40 am ET
CLASS ACTION UPDATE for CRCM, ZGNX, S and EQBK: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
May 22, 2019 05:20 am ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Orion, Zogenix, BrightView, and Eventbrite and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Orion Group Holdings, Inc., Zogenix, Inc., BrightView Holdings, Inc., and Eventbrite, Inc. Stockholders have until the...
May 21, 2019 04:38 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Zogenix, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Zogenix, Inc. ("Zogenix" or the "Company")(NASDAQ:ZGNX) of the June 11, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that...
May 20, 2019 03:25 pm ET
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zogenix, Inc. of Class Action Lawsuit and Upcoming Deadline – ZGNX
Pomerantz LLP announces that a class action lawsuit has been filed against Zogenix, Inc. (“Zogenix” or the “Company”) (NASDAQ: ZGNX) and certain of its officers and directors.   The class action, filed in United States District Court, United...
May 20, 2019 03:00 pm ET
SHAREHOLDER ALERT - Zogenix, Inc. (ZGNX) Bronstein, Gewirtz & Grossman, LLC Announces Class Action and Lead Plaintiff Deadline: June 11, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Zogenix, Inc. (“Zogenix” or the “Company”) (NASDAQ: ZGNX) and certain of its officers, on behalf of shareholders who...
May 20, 2019 10:40 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zogenix, Inc. (“Zogenix” or “the Company”) (NASDAQ: ZGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act...
May 17, 2019 06:00 am ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Orion, Zogenix, BrightView, and Eventbrite and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Orion Group Holdings, Inc., Zogenix, Inc., BrightView Holdings, Inc., and Eventbrite, Inc.  Stockholders have until the...
May 15, 2019 12:50 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Zogenix, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Zogenix, Inc. ("Zogenix" or the "Company")(NASDAQ:ZGNX) of the June 11, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
May 15, 2019 09:47 am ET
CLASS ACTION UPDATE for T, HCSG, NTNX and ZGNX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
May 14, 2019 05:26 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zogenix, Inc. of Class Action Lawsuit and Upcoming Deadline- ZGNX
NEW YORK, May 14, 2019 /CNW/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Zogenix, Inc. ("Zogenix" or the "Company") (NASDAQ: ZGNX) and certain of its officers and directors.  The class action, filed in United States District Court, United District Court, Northern District of California, and indexed under 19-cv-01975, is on behalf of a class consisting of all persons and entities, other than Defendants and their affiliates, who purchased or otherwise acquired Zogenix's securities between February 6, 2019 through April 8, 2019, both dates inclusive (the "Class...
May 14, 2019 05:26 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zogenix, Inc. of Class Action Lawsuit and Upcoming Deadline- ZGNX
NEW YORK, May 14, 2019 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Zogenix, Inc. ("Zogenix" or the "Company") (NASDAQ: ZGNX) and certain of its officers and directors.  The class action, filed in United States District Court, United District Court, Northern District of California, and indexed under 19-cv-01975, is on behalf of a class consisting of all persons and entities, other than Defendants and their affiliates, who purchased or otherwise acquired Zogenix's securities between February 6, 2019 through April 8, 2019, both dates inclusive (the...
May 13, 2019 04:40 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Zogenix, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Zogenix, Inc. ("Zogenix" or the "Company")(NASDAQ:ZGNX) of the June 11, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that...
May 13, 2019 04:20 pm ET
SHAREHOLDER ALERT: MBT NTNX ZGNX INVVY: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
May 13, 2019 02:45 pm ET
IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zogenix, Inc. (“Zogenix” or “the Company”) (NASDAQ: ZGNX) for violations of §§10(b) and 20(a) of the Securities Exchange Act...
May 12, 2019 09:29 am ET
LEAD PLAINTIFF DEADLINE: Johnson Fistel, LLP Encourages Investors Who Suffered Large Investment Losses to Contact the Firm
SAN DIEGO, May 12, 2019 /PRNewswire/ -- Johnson Fistel, LLP announces that class action lawsuits have been commenced on behalf of shareholders of the publicly-traded companies listed below. The Private Securities Litigation Reform Act of 1995 permits any investor who purchased a common stock during the Class Period to seek appointment as lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation.  The lead plaintiff can select a law firm of its choice.  An investor's ability to share in any potential future recovery is not dependent upon serving as...
May 10, 2019 05:00 am ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Orion, Zogenix, BrightView, and Eventbrite and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Orion Group Holdings, Inc., Zogenix, Inc., BrightView Holdings, Inc., and Eventbrite, Inc.  Stockholders have until the...
May 09, 2019 03:39 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zogenix, Inc. of Class Action Lawsuit and Upcoming Deadline – ZGNX
Pomerantz LLP announces that a class action lawsuit has been filed against Zogenix, Inc. (“Zogenix” or the “Company”) (NASDAQ: ZGNX) and certain of its officers and directors. The class action, filed in United States District Court, United District...
May 08, 2019 05:10 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of SCOR, MWA, and ZGNX of Upcoming Deadlines
Rigrodsky & Long, P.A. reminds investors of upcoming deadlines involving securities fraud class action lawsuits commenced against the following companies: comScore, Inc. (NASDAQ GS: SCOR) Class Period: November 8, 2018 - March 29, 2019Lead...
May 08, 2019 04:01 pm ET
Zogenix Provides Corporate Update and Reports First Quarter 2019 Financial Results
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced financial results for the three months ended March 31, 2019 and provided a corporate update. The Company will host a conference call...
May 07, 2019 01:54 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Zogenix, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Zogenix, Inc. ("Zogenix" or the "Company")(NASDAQ:ZGNX) of the June 11, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that...
May 07, 2019 10:10 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ZVO, CNDT, ZGNX and S
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
May 07, 2019 08:00 am ET
Zogenix to Participate in the Bank of America Merrill Lynch 2019 Healthcare Conference
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and CEO, and Michael P. Smith, Executive Vice President, CFO, Treasurer and Secretary, will...
May 03, 2019 05:49 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of SCOR, MWA, and ZGNX of Upcoming Deadlines
Rigrodsky & Long, P.A. reminds investors of upcoming deadlines involving securities fraud class action lawsuits commenced against the following companies: comScore, Inc. (NASDAQ GS: SCOR) Class Period: November 8, 2018 - March 29, 2019Lead...
May 03, 2019 03:52 pm ET
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Zogenix, Inc.
Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming June 11, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Zogenix, Inc. (“Zogenix” or the “Company”) (NASDAQ: 
May 03, 2019 10:30 am ET
CLASS ACTION UPDATE for CORT, WTW, CTL and ZGNX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
May 03, 2019 09:39 am ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Orion, Zogenix, BrightView, and Eventbrite and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Orion Group Holdings, Inc., Zogenix, Inc., BrightView Holdings, Inc., and Eventbrite, Inc.  Stockholders have until the...
May 02, 2019 05:48 pm ET
Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Zogenix, Inc.
Law Offices of Howard G. Smith reminds investors of the upcoming June 11, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Zogenix, Inc. (“Zogenix” or the “Company”) (NASDAQ: ZGNX) securities between February 6, 2019 and April 8, 2019, inclusive
May 02, 2019 05:45 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zogenix, Inc. of Class Action Lawsuit and Upcoming Deadline – ZGNX
Pomerantz LLP announces that a class action lawsuit has been filed against Zogenix, Inc. (“Zogenix” or the “Company”) (NASDAQ: ZGNX) and certain of its officers and directors.   The class action, filed in United States District Court, United...
May 02, 2019 04:29 pm ET
ZGNX CLASS ACTION ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Zogenix, Inc. - ZGNX
NEW YORK, May 2, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Zogenix, Inc. (NASDAQ: ZGNX) from February 6, 2019 through April 8, 2019, inclusive (the "Class Period"). The lawsuit seeks to recover damages for Zogenix investors under the federal securities laws....
May 01, 2019 08:03 pm ET
ZGNX CLASS ACTION REMINDER: Hagens Berman Reminds Zogenix (ZGNX) Investors of Securities Class Action, Encourages Investors Who Suffered Losses of $50,000+ to Contact the Firm
Hagens Berman Sobol Shapiro LLP, with 9 offices in 8 cities around the country and 80 attorneys, reminds investors in Zogenix, Inc. (NASDAQ: ZGNX) of the securities class action pending in the United States District Court for the Northern District...
May 01, 2019 04:47 pm ET
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has issued inducement awards to nine new non-executive employees.  The awards were made on May 1, 2019 under Zogenix’s...
May 01, 2019 03:44 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Zogenix, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Zogenix, Inc. ("Zogenix" or the "Company")(NASDAQ:ZGNX) of the June 11, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that...
May 01, 2019 08:00 am ET
Zogenix to Release First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 8
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the three months ended March 31, 2019, after the market close, and will host a corporate...
Apr 30, 2019 05:19 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing in Zogenix, Inc. to Contact the Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Zogenix, Inc. ("Zogenix" or the "Company") (NASDAQ:ZGNX) of the June 11, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Apr 29, 2019 03:30 pm ET
ZGNX DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Zogenix, Inc. – ZGNX
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Zogenix, Inc. (NASDAQ: ZGNX) from February 6, 2019 through April 8, 2019, inclusive (the “Class Period”). The lawsuit seeks to...
Apr 28, 2019 09:00 am ET
INVESTOR ALERT: Kaskela Law LLC Announces Important Shareholder Class Action Lawsuit Deadlines – BA, SCOR, MWA and ZGNX
Kaskela Law LLC announces that shareholder class action lawsuits have been filed against The Boeing Company (NYSE: BA), comScore, Inc. (Nasdaq: SCOR), Mueller Water Products, Inc. (NYSE: MWA) and Zogenix, Inc. (Nasdaq: ZGNX).  Additional...
Apr 26, 2019 03:54 pm ET
Glancy Prongay & Murray LLP Announces the Filing of a Securities Class Action on Behalf of Zogenix, Inc. Corporation Investors
Glancy Prongay & Murray LLP (“GPM”), a national investors rights law firm, announces that a class action lawsuit has been filed on behalf of investors that acquired Zogenix, Inc. (“Zogenix” or the “Company”) (NASDAQ:
Apr 26, 2019 06:00 am ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Orion, Zogenix, BrightView, and Eventbrite and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Orion Group Holdings, Inc., Zogenix, Inc., BrightView Holdings, Inc., and Eventbrite, Inc.  Stockholders have until the...
Apr 25, 2019 05:57 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Zogenix, Inc. Investors (ZGNX)
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Zogenix, Inc. (“Zogenix” or the “Company”) (NASDAQ: ZGNX) securities between February 6, 2019 and April 8, 2019, inclusive (the “Class Period”). Zogenix investors have until June 11, 2019 t
Apr 25, 2019 05:18 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Zogenix, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Zogenix, Inc. ("Zogenix" or the "Company")(NASDAQ:ZGNX) of the June 11, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that...
Apr 22, 2019 04:47 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Zogenix, Inc. To Contact The Firm
NEW YORK, April 22, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Zogenix, Inc. ("Zogenix" or the "Company")(NASDAQ:ZGNX) of the June 11, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company....
Apr 19, 2019 03:53 pm ET
ZGNX CLASS ACTION ALERT: Rosen Law Firm Reminds Zogenix, Inc. Investors of Important Deadline in Securities Class Action – ZGNX
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zogenix, Inc. (NASDAQ: ZGNX) from February 6, 2019 through April 8, 2019, inclusive (the “Class Period”) of the important June 11, 2019 lead plaintiff deadline in class action. The lawsuit seeks to recover damages for Zogenix investors under the federal securities laws.
Apr 19, 2019 10:47 am ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of EB, BV, ZGNX and MWA
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Apr 18, 2019 08:48 pm ET
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Zogenix, Inc. (“Zogenix” or “the Company”) (NASDAQ:
Apr 18, 2019 07:00 pm ET
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Zogenix, Inc. (ZGNX)
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Zogenix, Inc. (“Zogenix” or the “Company”) (Nasdaq: ZGNX) in the United States District Court for the Northern District of California on behalf of those who...
Apr 18, 2019 03:18 pm ET
Pawar Law Group Announces a Securities Class Action Lawsuit Against Zogenix, Inc. – ZGNX
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Zogenix, Inc. (NASDAQ: ZGNX) from February 6, 2019 through April 8, 2019, inclusive (the “Class Period”). The lawsuit seeks to...
Apr 18, 2019 02:51 pm ET
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Zogenix, Inc. of Class Action Lawsuit and Upcoming Deadline– ZGNX
Pomerantz LLP announces that a class action lawsuit has been filed against Zogenix, Inc. (“Zogenix” or the “Company”) (NASDAQ: ZGNX) and certain of its officers and directors.   The class action, filed in United States District Court, United...
Apr 18, 2019 12:21 pm ET
Robbins Arroyo LLP: Zogenix, Inc. (ZGNX) Misled Shareholders According to a Recently Filed Lawsuit
Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of Zogenix, Inc. filed a class action complaint against Zogenix, Inc. (NASDAQ: ZGNX) for alleged violations of the Securities Exchange Act of 1934 between February 6, 2019 and April 8, 2019. Zogenix is a pharmaceutical company that de
Apr 18, 2019 10:11 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of KHC, ZGNX, BA and MWA
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Apr 17, 2019 09:02 pm ET
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Zogenix, Inc. Investors (ZGNX)
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Zogenix, Inc. investors (“Zogenix” or the “Company”) (NASDAQ: ZGNX) concerning the Company and its officers’ possible violations of federal securities laws. If you are a...
Apr 17, 2019 04:50 pm ET
ZOGENIX, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of
Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of purchasers of the securities of Zogenix, Inc....
Apr 17, 2019 12:51 pm ET
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Zogenix, Inc.
Rigrodsky & Long, P.A.: Do you, or did you, own shares of Zogenix, Inc. (NASDAQ GM: ZGNX)? Did you purchase your shares between February 6, 2019 and April 8, 2019, inclusive? Did you lose money in your investment? Rigrodsky & Long, P.A. announces...
Apr 17, 2019 09:41 am ET
SHAREHOLDER ALERT: DPLO BV ZGNX MWA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Apr 16, 2019 08:03 pm ET
ZGNX CLASS ACTION ALERT: Hagens Berman Alerts Zogenix (ZGNX) Investors to Securities Class Action, Encourages Investors to Contact the Firm
SAN FRANCISCO, April 16, 2019 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Zogenix, Inc. (NASDAQ: ZGNX) to the securities class action pending in the United States District Court for the Northern District of California and to the June 11, 2019 Lead Plaintiff deadline.  If you purchased or otherwise acquired Zogenix securities between February 6, 2019 and April 8, 2019 and suffered losses contact Hagens Berman Sobol Shapiro LLP.  For more information about the case or to inquire about serving as Lead Plaintiff click...
Apr 16, 2019 05:00 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Zogenix, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Zogenix, Inc. ("Zogenix" or the "Company")(NASDAQ:ZGNX) of the June 11, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that...
Apr 16, 2019 04:17 pm ET
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Zogenix, Inc. – ZGNX
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Zogenix, Inc. (NASDAQ: ZGNX) from February 6, 2019 through April 8, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Zogenix investors under the federal securities laws.
Apr 16, 2019 10:38 am ET
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Zogenix, Inc.
Federman & Sherwood announces that on April 12, 2019, a class action lawsuit was filed in the United States District Court for the Northern District of California against Zogenix, Inc. (NASDAQ: ZGNX). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is February 6,
Apr 16, 2019 09:56 am ET
CLASS ACTION UPDATE for CAG, HCSG, ARA and ZGNX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Apr 15, 2019 08:07 pm ET
Hagens Berman Alerts Zogenix (ZGNX) Investors of the Firm's Investigation of Possible Securities Law Violations, Encourages Investors to Contact the Firm
SAN FRANCISCO, April 15, 2019 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Zogenix, Inc. (NASDAQ: ZGNX) to the firm's investigation of possible Federal securities law violations.  If you purchased or otherwise acquired Zogenix securities between January 1, 2019 and April 9, 2019 and suffered losses contact Hagens Berman Sobol Shapiro LLP.  For more information or to inquire about the investigation click...
Apr 15, 2019 01:06 pm ET
Investor Alert: Kaplan Fox Investigates Zogenix, Inc.
NEW YORK, April 15, 2019 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased shares of Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing rare disease therapies. Investors who purchased Zogenix securities between February 6, 2019 and April 8, 2019, inclusive (the "Class Period"), may be affected. A complaint has been filed in the United States District Court for the Northern District of California against the Company, its Chief Executive Officer, and its Chief Financial Officer....
Apr 15, 2019 10:30 am ET
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zogenix, Inc. (“Zogenix” or “the Company”) (NASDAQ: ZGNX) for violations of §§10(b) and 20(a) of the Securities...
Apr 15, 2019 08:45 am ET
INVESTOR ALERT: Kaskela Law LLC Announces Important Shareholder Class Action Lawsuit Deadlines – BA, SCOR, MWA and ZGNX
Kaskela Law LLC announces that shareholder class action lawsuits have been filed against The Boeing Company (NYSE: BA), comScore, Inc. (Nasdaq: SCOR), Mueller Water Products, Inc. (NYSE: MWA) and Zogenix, Inc. (Nasdaq: ZGNX).  Additional...
Apr 13, 2019 09:43 am ET
Former California Deputy Attorney General and Special Counsel with Johnson Fistel Launches Investigation into Zogenix, Inc. (ZGNX)
SAN DIEGO, April 13, 2019 /PRNewswire/ -- Johnson Fistel, LLP with the assistance of former California Deputy Attorney General and Special Counsel, Tiffany Johnson, Esq., is investigating potential claims against Zogenix, Inc. ("Zogenix") (NASDAQ: ZGNX) for violations of federal securities laws. ...
Apr 12, 2019 09:00 pm ET
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Zogenix, Inc. (ZGNX) and Encourages ZGNX Investors to Contact the Firm
Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired Zogenix, Inc. (NASDAQ:...
Apr 12, 2019 04:27 pm ET
Pomerantz Law Firm Announces the Filing of a Class Action against Zogenix, Inc. and Certain Officers – ZGNX
Pomerantz LLP announces that a class action lawsuit has been filed against Zogenix, Inc. (“Zogenix” or the “Company”) (NASDAQ: ZGNX) and certain of its officers and directors.   The class action, filed in United States District Court, United...
Apr 12, 2019 01:29 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zogenix, Inc. - ZGNX
Pomerantz LLP is investigating claims on behalf of investors of Zogenix, Inc. (“Zogenix” or the “Company”) (NASDAQ: ZGNX).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980. The...
Apr 12, 2019 08:00 am ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Zogenix, Inc. Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Zogenix, Inc. investors (“Zogenix” or the “Company”) (NASDAQ: ZGNX) concerning the Company and its officers’ possible violations of federal securities laws.
Apr 11, 2019 10:25 pm ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zogenix, Inc. (“Zogenix” or “the Company”) (NASDAQ:
Apr 11, 2019 03:00 pm ET
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Zogenix, Inc. Investors (ZGNX)
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Zogenix, Inc. investors (“Zogenix” or the “Company”) (NASDAQ: ZGNX) concerning the Company and its officers’ possible violations of federal securities laws.
Apr 10, 2019 09:05 pm ET
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Zogenix, Inc. Investors (ZGNX)
Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Zogenix, Inc. investors (“Zogenix” or the “Company”) (NASDAQ: ZGNX) concerning the Company and its officers’ possible violations of federal securities laws.
Apr 10, 2019 08:04 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Zogenix, Inc. Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Zogenix, Inc. investors (“Zogenix” or the “Company”) (NASDAQ: ZGNX) concerning the Company and its officers’ possible violations of federal securities laws.
Apr 10, 2019 08:00 pm ET
Bragar Eagel & Squire, P.C. is Investigating Zogenix, Inc. (ZGNX) on Behalf of Stockholders and Encourages ZGNX Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against Zogenix, Inc. (NASDAQ: ZGNX).  Our investigation concerns whether Zogenix has violated the federal securities laws and/or engaged in other unlawful business practices. Click...
Apr 10, 2019 06:41 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zogenix, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zogenix, Inc. (“Zogenix” or “the Company”) (NASDAQ:
Apr 10, 2019 12:25 pm ET
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Zogenix, Inc. – ZGNX
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Zogenix, Inc. (NASDAQ: ZGNX) resulting from allegations that Zogenix may have issued materially misleading business information to the investing public.
Apr 10, 2019 11:30 am ET
Zogenix Investigated by Block & Leviton LLP For Violations of Federal Securities Laws
Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, is investigating whether Zogenix, Inc. (“Zogenix” or the “Company”) (NASDAQ: ZGNX) and certain of its officers and directors violated federal...
Apr 09, 2019 05:50 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zogenix, Inc. - ZGNX
NEW YORK, April 9, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zogenix, Inc. ("Zogenix" or the "Company") (NASDAQ: ZGNX).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980....
Apr 09, 2019 05:50 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zogenix, Inc. - ZGNX
NEW YORK, April 9, 2019 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors of Zogenix, Inc. ("Zogenix" or the "Company") (NASDAQ: ZGNX).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980....
Apr 08, 2019 04:01 pm ET
Zogenix Receives Refusal to File Letter from U.S. Food and Drug Administration for FINTEPLA® New Drug Application
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application...
Apr 01, 2019 05:17 pm ET
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has issued inducement awards to five new non-executive employees.  The awards were made on April 1, 2019 under Zogenix’s...
Mar 25, 2019 08:00 am ET
Zogenix to Present at Two Investor Conferences in April
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that members of management will participate on panels and host investor meetings at two conferences in April: Stifel First Annual CNS...
Mar 19, 2019 08:00 am ET
Zogenix Enters Exclusive Distribution Agreement with Nippon Shinyaku for FINTEPLA® in Japan
Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has entered into an exclusive distribution agreement with Nippon Shinyaku, Co., Ltd., a leading Japanese pharmaceutical product...
Mar 18, 2019 09:31 am ET
Option-trading opportunities on The Boeing Co., Coty Inc., Microsoft Corp., Rite Aid Corp., and Zogenix Inc.
NEW YORK, March 18, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BA, COTY, MSFT, RAD, and ZGNX....
Mar 06, 2019 07:40 am ET
Research Report Identifies Zogenix, LivePerson, Valmont Industries, Carnival, Inphi, and Westlake Chemical Partners LP with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Zogenix, Inc. (NASDAQ:ZGNX), LivePerson, Inc. (NASDAQ:LPSN), Valmont...
Mar 01, 2019 04:51 pm ET
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has issued inducement awards to five new non-executive employees.  The awards were made on March 1, 2019 under Zogenix’s...
Feb 28, 2019 04:01 pm ET
Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2018 Financial Results
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today provided a corporate update and announced financial results for the fourth quarter and full-year ended December 31, 2018. “We are pleased that...
Feb 21, 2019 08:00 am ET
Zogenix to Release Fourth Quarter and Full-Year 2018 Financial Results and Host Conference Call and Webcast on February 28
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2018, after the market close, and...
Feb 20, 2019 08:00 am ET
Zogenix to Present at the 8th Annual SVB Leerink Global Healthcare Conference
Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that Stephen J. Farr, President and CEO, will provide a corporate update at the 8th Annual SVB Leerink Global Healthcare Conference,...
Feb 06, 2019 08:00 am ET
Zogenix Submits New Drug Application to U.S. Food & Drug Administration and Marketing Authorization Application to European Medicines Agency for FINTEPLA® for the Treatment of Dravet Syndrome
Zogenix, Inc. (NASDAQ:ZGNX), a global pharmaceutical company developing rare disease therapies, today announced it has completed its rolling submission of a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) and submitted a...
Feb 01, 2019 04:43 pm ET
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it has issued inducement awards to four new non-executive employees.   The awards...
Jan 14, 2019 07:30 am ET
Detailed Research: Economic Perspectives on Advanced Micro Devices, Blackbaud, United States Cellular, CalAmp, Visteon, and Zogenix — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Advanced Micro Devices, Inc. (NASDAQ:AMD), Blackbaud, Inc....
Jan 02, 2019 04:05 pm ET
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it has issued inducement awards to two new non-executive employees.  The awards were...
Dec 17, 2018 07:25 am ET
New Research: Key Drivers of Growth for Ashland Global, Intellia Therapeutics, Thor Industries, Zogenix, BWX Technologies, and Heidrick & Struggles International — Factors of Influence, Major Initiati
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Ashland Global Holdings Inc. (NYSE:ASH), Intellia Therapeutics, Inc....
Dec 03, 2018 04:05 pm ET
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it has issued inducement awards to three new non-executive employees.   The awards...
Dec 03, 2018 09:00 am ET
Zogenix Announces Positive Phase 3 Trial Results on the Efficacy and Safety of FINTEPLA® (ZX008) in Dravet Syndrome
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare diseases, announced today that late-breaking data will be presented on the use of its investigational drug, FINTEPLA® (ZX008; low-dose...
Dec 02, 2018 09:00 am ET
Zogenix Presents Positive Findings on the Impact of Treatment with FINTEPLA® (ZX008) on Everyday Executive Function in Patients with Dravet Syndrome
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare diseases, today announced results from a post-hoc analysis of its investigational drug, FINTEPLA® (ZX008), on caregiver-reported everyday...
Nov 29, 2018 08:00 am ET
Zogenix to Host Investor Update Lunch on FINTEPLA® at the American Epilepsy Society 2018 Annual Meeting
Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare diseases, today announced that it will host an Investor Update Lunch on FINTEPLA® (ZX008) on Monday, December 3, 2018, from 12:00 PM to 2:00 PM...
Nov 27, 2018 08:00 am ET
Zogenix to Participate in the Global Mizuho Investor Conference 2018
Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Michael P. Smith, Executive Vice President, Chief Financial Officer, Treasurer and...
Nov 26, 2018 08:00 am ET
Zogenix to Announce New Data at 72nd American Epilepsy Society Annual Meeting
Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare diseases, today announced that data from nine abstracts, including four “late-breakers,” will be presented at the 72nd American Epilepsy Society...
Nov 15, 2018 08:55 am ET
Investor Expectations to Drive Momentum within Berkshire Hathaway, Zogenix, ICC, CIRCOR International, Principia Biopharma, and Technical Communications — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Berkshire Hathaway Inc. (NYSE:BRK.A), Zogenix, Inc. (NASDAQ:ZGNX), ICC...
Nov 08, 2018 04:01 pm ET
Zogenix Provides Corporate Update and Reports Third Quarter Financial Results
Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today provided a corporate update and announced financial results for the third quarter and nine months...
Nov 07, 2018 08:00 am ET
Zogenix to Present at Stifel 2018 Healthcare Conference
Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, and Michael P. Smith, Executive Vice...
Nov 01, 2018 08:00 am ET
Zogenix to Release Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 8
Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the third quarter ended September 30, 2018,...
Oct 01, 2018 05:07 pm ET
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it has issued inducement awards to three new non-executive employees. The awards...
Sep 25, 2018 08:00 am ET
Zogenix to Present at LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology
Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, and Michael P. Smith, Executive Vice...
Sep 04, 2018 04:38 pm ET
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it has issued inducement awards to four new non-executive employees. The awards were...
Sep 04, 2018 08:00 am ET
Zogenix Phase 2 Study Results Published in Epilepsia Show ZX008 Provides Durable Reduction in Seizure Frequency in Patients With Lennox-Gastaut Syndrome
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that detailed results of the Phase 2, open-label study evaluating its investigational drug,...
Aug 30, 2018 08:00 am ET
Zogenix Announces New Data on Psychological and Socioeconomic Impact of Dravet Syndrome and Other Epileptic Encephalopathies at 13th European Congress on Epileptology
Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced new findings from multiple studies assessing the psychological and socioeconomic impact of...
Aug 07, 2018 06:21 pm ET
Zogenix Prices Public Offering of Common Stock
Zogenix, Inc. (Nasdaq: ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, announced today that it has priced an underwritten public offering of 6,000,000 shares of its common...
Aug 06, 2018 05:14 pm ET
Zogenix Announces Proposed Public Offering of 6,000,000 Shares of Common Stock
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, announced today that it intends to offer and sell, subject to market and other conditions, 6,000,000...
Aug 06, 2018 04:26 pm ET
Zogenix Provides Corporate Update and Reports Second Quarter Financial Results
Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today provided a corporate update and announced financial results for the second quarter and six months...
Aug 01, 2018 04:29 pm ET
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it has issued inducement awards to five new non-executive employees.  The awards were...
Aug 01, 2018 08:00 am ET
Zogenix to Release Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 6
Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the second quarter ended June 30, 2018,...
Jul 12, 2018 07:00 am ET
Zogenix Announces Positive Top-line Results from Second Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today reported positive top-line results from its second confirmatory Phase 3 study (Study 1504) for its...
Jul 02, 2018 04:32 pm ET
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it has issued an inducement award to Ashish Sagrolikar, the company’s newly appointed...
Jul 02, 2018 08:00 am ET
Zogenix Welcomes New Global Chief Commercial Officer
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Ashish Sagrolikar has joined the Company as Executive Vice President and Chief...
Jun 01, 2018 04:24 pm ET
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it has issued inducement awards to four new non-executive employees.  The awards were...
May 14, 2018 08:00 am ET
Zogenix to Participate in the Bank of America Merrill Lynch 2018 Healthcare Conference
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, and Michael P. Smith, Executive Vice...
May 09, 2018 04:01 pm ET
Zogenix Provides Corporate Update and Reports First Quarter Financial Results
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today provided a corporate update and announced financial results for the first quarter ended March 31,...
May 04, 2018 08:00 am ET
Zogenix to Release First Quarter 2018 Financial Results and Host Conference Call and Webcast on May 9
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter ended March 31, 2018, after...
May 01, 2018 05:00 pm ET
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
EMERYVILLE, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it has issued inducement awards to six new non-executive...
Apr 27, 2018 08:00 am ET
Zogenix Announces Initial Quality of Life and Cognitive Function Data From Phase 3 Trial of ZX008 in Dravet Syndrome
ZX008 Patients Experienced Significant Improvements on Select Measures of Quality of Life and Executive Function Compared to Those on Placebo
Apr 25, 2018 08:00 am ET
Report: Exploring Fundamental Drivers Behind Urban Edge Properties, FLIR, Zogenix, Watts Water Technologies, CDW, and BMC Stock — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, April 25, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Urban Edge Properties (NYSE:UE), FLIR Systems,...
Apr 25, 2018 08:00 am ET
Zogenix Announces Presentation of New Efficacy and Safety Data from its First Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
Efficacy and Safety Data in Patients on ZX008 Who Previously Failed Stiripentol Treatment Prior to Entry into First Phase 3 Trial (Study 1) Comparable to Results from Full Study 1 Population
Apr 11, 2018 08:00 am ET
Zogenix to Participate in LEERINK Partners CNS Day
EMERYVILLE, Calif., April 11, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, Gail Farfel,...
Mar 06, 2018 04:01 pm ET
Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results
EMERYVILLE, Calif., March 06, 2018 (GLOBE NEWSWIRE) --  Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today provided a corporate update and announced financial results for the fourth...
Mar 01, 2018 08:25 am ET
Report: Developing Opportunities within Inseego, Cato, FleetCor Technologies, Zogenix, Verisk Analytics, and XPO Logistics — Future Expectations, Projections Moving into 2018
NEW YORK, March 01, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Inseego Corp. (NASDAQ:INSG), Cato Corporation (NYSE:CATO),...
Feb 27, 2018 08:00 am ET
Zogenix to Release Fourth Quarter and Full-Year 2017 Financial Results and Host Conference Call and Webcast on March 6
EMERYVILLE, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the fourth...
Feb 08, 2018 08:00 am ET
Zogenix to Participate in Leerink Partners 7th Annual Global Healthcare Conference
EMERYVILLE, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, and Michael...
Feb 06, 2018 08:00 am ET
Zogenix Announces Receipt of FDA Breakthrough Therapy Designation for ZX008 in Dravet Syndrome
Designation Based on Positive Results from Study 1, the First Pivotal Phase 3 Trial of ZX008
Jan 31, 2018 04:05 pm ET
Jan 04, 2018 08:30 am ET
Analysis: Positioning to Benefit within FleetCor Technologies, Zogenix, BioTelemetry, Modine Manufacturing, Navigant Consulting, and CalAmp — Research Highlights Growth, Revenue, and Consolidated Resu
NEW YORK, Jan. 04, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of FleetCor Technologies, Inc. (NYSE:FLT), Zogenix, Inc....
Dec 04, 2017 08:00 am ET
Zogenix Announces New Positive Efficacy and Safety Data from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
ZX008 Patients More Likely to Achieve Clinically Meaningful Reduction in Seizure Frequency Compared to Those on Placebo
Nov 29, 2017 08:05 am ET
Zogenix Announces Initiation of Phase 3 Trial for ZX008 in Lennox-Gastaut Syndrome
EMERYVILLE, Calif., Nov. 29, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that the first child has enrolled in the Phase 3...
Nov 29, 2017 08:00 am ET
Zogenix to Participate in the Global Mizuho Investor Conference 2017
EMERYVILLE, Calif., Nov. 29, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, and Michael...